Fresenius Medical Care highlights real-world advances in hemodiafiltration and AI at ASN Kidney Week 2025
Fresenius Medical Care (NYSE:FMS) will present new real-world research at ASN Kidney Week 2025 (Nov 5-9) showing that hemodiafiltration (HDF) is associated with reduced cardiovascular- and fluid-related hospitalizations and that AI tools can support clinical care. Presentations include an oral abstract on HDF outcomes, the first U.S. chronic unit implementing high-volume HDF, an AI model predicting 31-day fall risk, a clinician-facing AI chatbot for HDF, and an evaluation of generative AI for dialysis diet planning.
The company also will host symposiums and booth events and notes its global footprint of ~4.2M dialysis patients and 3,676 clinics.
Fresenius Medical Care (NYSE:FMS) presenterà nuove ricerche nel mondo reale alla ASN Kidney Week 2025 (5-9 novembre) mostrando che l'emodialfiltrazione (HDF) è associata a una riduzione delle ospedalizzazioni correlate al sistema cardiovascolare e ai fluidi e che gli strumenti di AI possono supportare la cura clinica. Le presentazioni includono un abstract orale sugli esiti dell'HDF, la prima unità cronica statunitense ad implementare l'HDF ad alto volume, un modello di IA che predice il rischio di caduta a 31 giorni, un chatbot IA rivolto ai clinici per l'HDF e una valutazione dell'IA generativa per la pianificazione della dieta di dialisi.
L'azienda ospiterà anche simposi ed eventi allo stand e segnala la propria impronta globale di circa ~4,2M pazienti in dialisi e 3.676 cliniche.
Fresenius Medical Care (NYSE:FMS) presentará nueva investigación del mundo real en la ASN Kidney Week 2025 (del 5 al 9 de noviembre), mostrando que la hemodiafiltración (HDF) se asocia con una reducción de las hospitalizaciones por problemas cardiovasculares y relacionados con el líquido, y que las herramientas de IA pueden apoyar la atención clínica. Las presentaciones incluyen un resumen oral sobre los resultados de HDF, la primera unidad crónica de EE. UU. que implementa HDF de alto volumen, un modelo de IA que predice el riesgo de caídas a 31 días, un chatbot de IA para clínicos para HDF y una evaluación de IA generativa para la planificación de la dieta de diálisis.
La empresa también organizará simposios y eventos en el stand y señala su presencia global de aproximadamente 4,2M pacientes en diálisis y 3.676 clínicas.
Fresenius Medical Care (NYSE:FMS)는 ASN Kidney Week 2025 (11월 5-9일)에 실제 세계 연구를 새롭게 발표할 예정이며, 혈류여과(HDF)가 심혈관 관련 및 체액 관련 입원 감소와 연관되어 있음을 보여주고 AI 도구가 임상 치료를 지원할 수 있음을 시사합니다. 발표에는 HDF 결과에 대한 구두 초록, 고용량 HDF를 도입하는 미국의 첫 만성 단위, 31일 낙상 위험을 예측하는 AI 모델, HDF를 위한 임상의용 AI 채팅봇, 그리고 투석 다이어트 계획에 대한 생성형 AI 평가가 포함됩니다.
또한 회사는 심포지엄 및 부스 이벤트를 주최하고 전 세계에 약 ~4.2M명의 투석 환자와 3,676개의 진료소를 보유하고 있다고 밝혔습니다.
Fresenius Medical Care (NYSE:FMS) présentera de nouvelles recherches réelles lors de l'ASN Kidney Week 2025 (du 5 au 9 novembre), montrant que l'hémodialfiltration (HDF) est associée à une réduction des hospitalisations liées au système cardiovasculaire et au liquide, et que les outils d'IA peuvent soutenir les soins cliniques. Les présentations incluent un résumé oral sur les résultats de l'HDF, la première unité chronique américaine mettant en œuvre l'HDF à haut volume, un modèle d'IA prédisant le risque de chute sur 31 jours, un chatbot d'IA destiné aux cliniciens pour l'HDF et une évaluation de l'IA générative pour la planification diététique de la dialyse.
L'entreprise organisera également des symposiums et des événements au stand et souligne son empreinte mondiale d'environ 4,2M patients dialysés et 3 676 cliniques.
Fresenius Medical Care (NYSE:FMS) wird neue Real-World-Forschung bei der ASN Kidney Week 2025 (5.–9. November) vorstellen und zeigen, dass die Hämofiltration (HDF) mit reduzierten kardiovaskulären- und flüssigkeitsbedingten Krankenhausaufenthalten verbunden ist und dass KI-Tools die klinische Versorgung unterstützen können. Die Präsentationen umfassen einen mündlichen Abstract zu HDF-Ergebnissen, die erste US-amerikanische chronische Abteilung, die Hochvolumen-HDF implementiert, ein KI-Modell, das das Sturzrisiko in 31 Tagen vorhersagt, einen KI-Chatbot für Kliniker im Zusammenhang mit HDF und eine Bewertung von Generative AI für die Diätplanung bei der Dialyse.
Das Unternehmen wird auch Symposien und Stand-Veranstaltungen ausrichten und verweist auf seine globale Reichweite von ca. 4,2 Mio. Dialysepatienten und 3.676 Kliniken.
سيقدِّم Fresenius Medical Care (بورصة نيويورك:FMS) أبحاثاً جديدة من الواقع الحقيقي في أسبوع ASN Kidney Week 2025 (5-9 نوفمبر)، مُظهِراً أن الترشيح الدموي بالكيميا (HDF) مرتبط بتقليل الإقامات في المستشفيات المرتبطة بالقلب والسوائل، وأن أدوات الذكاء الاصطناعي يمكن أن تدعم الرعاية السريرية. تتضمن العروض ملخصاً شفهيّاً لنتائج HDF، أول وحدة مزمنة أميركية تُنفِّذ HDF عالي التدفق، نموذج ذكاء اصطناعي يتنبأ بخطر السقوط خلال 31 يوماً، روبوت محادثة AI مخصص للأطباء لـ HDF، وتقييمًا للذكاء الاصطناعي التوليدي لتخطيط النظام الغذائي للغسيل الكلوي.
كما ستستضيف الشركة ندوات وفعاليات في الجناح وتُشير إلى حضورها العالمي بما يقرب من 4.2M مريض غسيل كلوي و3,676 عيادة.
- HDF linked to reduced cardiovascular- and fluid-related hospitalizations
- First U.S. chronic dialysis unit reported high-volume HDF implementation
- AI model predicts 31-day fall risk for dialysis patients
- Clinician-facing AI chatbot introduced to support HDF adoption
- None.
Insights
Real-world data links high-volume HDF to fewer cardiovascular and fluid-related hospitalizations; AI tools move toward clinical use.
The research portfolio focuses on translating hemodiafiltration (HDF) from controlled trials into routine care by reporting associations between HDF and reduced cardiovascular- and fluid-related hospital admissions and by describing the first U.S. chronic unit implementing high-volume HDF. These findings, presented as abstracts including an oral presentation, strengthen the clinical argument for broader HDF adoption if the associations hold across settings.
Dependencies and risks include observational design and generalizability: association does not prove causation and outcomes may depend on patient selection, protocol consistency, and center experience. Watch for published abstracts or full posters at ASN Kidney Week on
AI demonstrations aim to support clinicians with fall-risk prediction and an evidence-verified chatbot, moving models into operational use.
Presentations include an AI model predicting 31-day fall risk, a clinician-facing AI chatbot citing verified clinical sources, and an assessment of generative models for dialysis diet planning. These items show focus on practitioner workflows and patient safety rather than speculative research only.
Key caveats are validation, integration, and regulatory alignment: model performance metrics, prospective validation, and clinician uptake will determine usefulness. Track the conference materials and any subsequent peer-reviewed validation or real-world deployment data over the next 6-18 months to judge clinical readiness and operational impact.
- Fresenius Medical Care researchers will present multiple abstracts that demonstrate proven, real-world benefits of hemodiafiltration (HDF), with one accepted as an oral presentation.
- Oral presentation highlights the association between HDF and reduced risk of cardiovascular and fluid-related hospitalization outcomes.
- Research shows how artificial intelligence is moving from theory into practice, supporting clinicians and patients in daily kidney disease care.
BAD HOMBURG,
"This research reflects Fresenius Medical Care's commitment to patient-centered innovation, demonstrating how advanced therapies like hemodiafiltration can be tailored to improve outcomes in real-world settings," said Frank Maddux, MD, Global Chief Medical Officer at Fresenius Medical Care. "By applying novel physical principles to kidney replacement therapy, we are leading the field in delivering transformative solutions that elevate the standard of care and advance precision medicine globally."
FME's Global Medical Office will present multiple abstracts across a range of critical topics in nephrology, underscoring the company's commitment to advancing kidney care through innovation and evidence-based science.
Key presentations include:
- Hemodiafiltration is associated with reduced risk of cardiovascular and fluid-related hospitalization outcomes: Highlights how HDF may lower the risk of cardiovascular- and fluid-related hospitalizations.
-
Implementation of Online High-Volume Hemodiafiltration in a Chronic Hemodialysis Center in the
U.S. : Describes the first chronic dialysis unit to introduce high-volume HDF in theU.S. - Preventing Falls in Patients on Dialysis Through Artificial Intelligence (AI)-Driven Risk Prediction: Showcases an AI model that predicts patients' fall risk within a 31-day period.
- Supporting Clinician Adoption of Hemodiafiltration: A Real-Time Artificial Intelligence (AI) Chatbot with Verified Clinical Sources: Introduces a clinician-facing AI chatbot designed to educate and support clinicians implementing HDF.
- From Prompt to Plate: Can ChatGPT Plan a Safe and Clinically Appropriate Diet for Hemodialysis Patients?: Evaluates whether generative AI and large language models can provide safe, nutritionally accurate meal plans for dialysis patients.
"It excites us to see how our research and innovation can translate to everyday practice," said Maddux. "By combining real-world evidence with innovative technologies, Fresenius Medical Care is helping shape the future of nephrology and set new standards for kidney care."
In addition to scientific presentations, FME will participate in the following events during ASN Kidney Week:
- FME will host a breakfast symposium, "HighVolumeHDF: The Next Standard of Care for
U.S. Patients – Evidence and Practical Use," as part of the ASN Exhibitor Spotlight series (Thursday, November 6). - ASN will present an educational symposium, "Hemodiafiltration: Considerations for Incorporation into Dialysis Care," supported by an educational grant from Fresenius Medical Care (Friday, November 7).
- The Renal Research Institute (RRI), a subsidiary of Fresenius Medical Care, will host its annual symposium, "Reimagining Frontline Care: The Power of Research, AI, and Innovation," highlighting real-world applications of AI and digital tools in kidney care (Tuesday, November 4).
FME leaders and researchers will also be available onsite at Booth #1815 to discuss research insights, clinical collaborations, and innovations in kidney care. Representatives from RRI will be available at Booth #1838.
To learn more about the company's presence at ASN this year, please visit https://freseniusmedicalcare.com/en-us/asn-2025/.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,676 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 300,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company's website at www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the
Media contact
Kirsten Stratton
T +1 781 929 8096
kirsten.stratton@freseniusmedicalcare.com
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com
Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2525
Dominik.Heger@FreseniusMedicalCare.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-highlights-real-world-advances-in-hemodiafiltration-and-ai-at-asn-kidney-week-2025-302599436.html
SOURCE Fresenius Medical Care Holdings, Inc.
FAQ
What did Fresenius Medical Care (FMS) announce for ASN Kidney Week 2025 on Nov 5-9?
How does the ASN oral presentation affect FMS (NYSE:FMS) clinical credibility on HDF?
What AI innovations will FMS (FMS) showcase at ASN Kidney Week 2025?
When and where will Fresenius host its HDF symposium at ASN 2025?
Does Fresenius Medical Care report any implementation of high-volume HDF in the U.S.?
How large is Fresenius Medical Care's global dialysis footprint referenced in the announcement?
